Stempeutics Receives US Process Patent for Its Novel Stem Cell Drug "Stempeucel(R)"

Stempeucel will initially be used for the treatment of CLI and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself. Critical Limb Ischemia is a progressive form of peripheral arterial disease, which blocks the arteries in the lower extremities, resulting into reduction of the blood flow.

http://ift.tt/1AK4lpE